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Significant discoveries and developments, though often chronologically dependent, flowed in a rapid stream from the Laboratory with: isolation of the causative virus by 1967; isolation of the herpesvirus of turkeys (HVT) and laboratory demonstration of its ability to protect against the lesions of Marek's disease, both in 1969; field trials of HVT vaccine in 1970; and licensing by state for use in Michigan in late 1970 and by the USDA Animal and Plant Health Inspection Service for national use in early 1971. These important contributions in this field are summarized in Table I . Because of the quality of the research results and the great need of the poultry industry for a prophylactic against Marek's disease, the time required to adopt this new technology was much shorter than that required to adapt many other agricultural discoveries ( Table 2) . The time between the development of the HVT vaccine and its adoption by the industry was only about 2 years. In contrast, the time between the development of many other agricultural discoveries and their adoption has been as long as one or more decades (Wittwer, S . 1975) . The cost of the research and the benefits to 1J.S. agriculture will now be examined in detail.
Cost of Marek's Disease Research
The total expenditure of the public sector on avian leukosis research (primarily research on Marek's disease) during the 10-year span froin 1965 This total is estimated to have been matched by research in the private sector on these problems; thus, the total research investment over the 10-year period was $32 million. The figures include the effort on lymphoid leukosis, which was estimated to have been over 50 per cent of the effort in 1965 but declined to only 10 per cent by 1970. Because the relative level of research effort on Marek's disease and lymphoid leukosis is only a rough estimate, the effort on lymphoid leukosis has been included so as to be conservative in the estimate of benefit to cost ratio. When the physical proportion of product saved is applied to the total market value, the result is a measure of the value of additional product obtained by use of the vaccine over what would have been produced with the same quantity of production inputs (chicks, feed, labour, capital, etc.) without the vaccine. The effect of the technology on the market price of the product is partly accounted for although the impact of the market price change on production input levels is not measured by this approach. Other factors that affect the price may inadvertently be included; e.g., other diseases, such as the exotic Newcastle disease outbreak, and variations in demand. However, the benefits are estimated in terms of the average market conditions operating during that year. The benefits reflect the increased production 20 1 efficiency and reduced cost of production. All dollar benefits should be viewed as rough estimates and are not highly precise.
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Because the vaccine is applied when chicks are 1 day old and broilers are marketed when they are 8 weeks old, or eggs are marketed when hens are between 20 and 80 weeks old, there is a delay between expenditures and returns on vaccination. But broiler and egg production are year-round operations with only minor seasonal fluctuations in quantity and value, so this lag would have minimal effect on the value of benefits obtained from vaccination.
Benefits from the vaccine resulted first in 1971. These totalled $30 million, almost enough to pay for the entire 10 years of research by both the public and private sectors. By 1974, the first year of full adoption, the gross benefits were $628 million. The net benefits stemming from use of the vaccine since 1974 are estimated to total $168 million annually ( Table 3) . If these benefits are projected to last for at least another 10 years before the vaccine is replaced by other technology, the total of net benefits by 1983 would be $2 billion. If future research is projected to remain level at the $4.3 million estimated to have been spent by both public and private sectors in 1974, the total cost of research by 1983 will be $70 million. Even if we assumed that there will be no further benefits by 1983 from the continued research in this field, the benefits and costs cited are such that, if the benefits could be allocated entirely to the research, the internal rate of return over the 20-year period would be 88 per cent or a rate of interest of 88 per cent compounded annually. Expressed another way, if both costs and benefits are discounted at a reasonable cost of capital rate of 7 per cent annually to the beginning in 1965, the ratio of benefits to costs is 22:l. Even if costs from the beginning of the Laboratory from 1939 through 1965 were considered (the ARS part was less than $6 million), and even if only the benefits from the Marek's disease vaccine as delineated here were considered, and even if the total cost over the entire period was four times the ARS cost as in recent years, the picture would not change radically. The benefit to cost ratio would still be about 4:1 when discounted at 7 per cent to 1939. The total time to obtain these benefits, the suddenness with which they came when a certain level of basic knowledge was reached, and the immensity of the benefits finally obtained, all combine to illustrate the difficulties that decision makers experience in allocating research resources.
The benefits from Marek's disease research are undoubtedly larger than were expected at the inception of the research programme. In fact, the use of the vaccine soon resulted in an over-production of poultry meat and eggs which, in turn, resulted in a severe drop in prices. However, supply and demand have since stabilized, and the benefits are now spread to the population at large in the form of a decrease in the cost of production of each broiler and each dozen of eggs. As a result, consumers can purchase poultry products at less cost than they could have without these discoveries. Individual producers in the industry may or may not have benefited in the short run, depending upon how rapidly they adopted the new technology. After the short-run economic adjustment problems were overcome, the poultry industry as a whole, however, gained some long-run benefits in terms of its competitive position in relation to that of other foods. Also, the nation has benefited because fewer resources are necessary to produce the same number of broilers and eggs that were produced before the discoveries, with attendant conservation of natural resources and availability of additional human resources for other uses. Other members of society, notably the vaccine producers, gain indirect benefits.
In addition to the tangible benefits already discussed, there are many intangible benefits. One is the more predictable growth of chickens. Another is the impact of this research on other scientists in various fields, particularly on human cancer research.
Conclusions
The Agricultural Research Service began a programme of increased research emphasis on Marek's disease of chickens in 1965. This programme led to the development and full adoption by 1974 of a vaccine that successfully controls the disease. The savings and increased production made possible by this vaccine by 1974 were sufficient to represent a return of 83 per cent compounded annually on the total research investment, public and private, on this problem and its related disease, lymphoid leukosis, between 1965 and 1974. If we assumed that the benefits of $168 million experienced in 1974 from Marek's disease alone will continue for 10 years before the vaccine is replaced by some other technology and that the total of all research efforts will continue at the 1974 level of $4.3 million, then the total estimated returns made possible by this research would be sufficient to support a return of 88 203 per cent compounded annually on the total invested in this research over the 20-year period. This estimate does not involve any assumption about possible additional benefits from the continued research.
The development of a vaccine against Marek's disease could not ha\e been predicted when research was begun in 1939, not even when the etiology of Marek's disease was uncovered in 1969. Nevertheless, managerial foresight led to increasing financial support to this project. This support is undoubtedly an example of intelligent resource allocation. It is also an example of how investment in agricultural research can benefit the producer, the consumer, and society in general.
Summary
A vaccine for the control of Marek's disease, a disease causing severe losses in poultry worldwide, was developed and made available for national use in the United States in 1971. This paper examines the benefits and costs of the control 01 Marek's disease in the United States.
The total public and private (including industry) expenditure on avian leukosis research for a 10-year period was estimated. Then the total benefits from the research up to 1974 were estimated from the reduced broiler and egg-type chicken losses and increased egg production and feed utilization. The total expenditure on research between 1965 and 1974 was about $32 million. Benefits from the control of the disease are estimated to total $168 million annually. If both costs and benefits are discounted at a reasonable rate of 7 per cent annually to the beginning of increased effort against Marek's disease in 1965, the ratio of benefits to costs is 22:l. Even if costs and benefits are discounted to the beginning of Federal work against avian leukosis in 1939 the ratio would be 4:l. In addition, there were many intangible benefits such as the more predictable growth of chickens and the impact of the research on science in other fields such as human cancer. By any measure, the investment in research on avian tumours has paid off handsomely. The greatest benefit was to the consumer in the form of a more uniform, less expensive product than would have been available had the technology not been developed. 
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